Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
12.63
-1.14 (-8.28%)
Sep 1, 2026, 4:00 PM EDT - Market closed
Kazia Therapeutics Employees
Kazia Therapeutics had 6 employees as of June 30, 2025. The number of employees decreased by 1 or -11.76% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-11.76%
Revenue / Employee
$211,072
Profits / Employee
-$2,534,761
Market Cap
144.32M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 6 | -1 | -11.76% |
| Jun 30, 2024 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| LENZ Therapeutics | 152 |
| Tenaya Therapeutics | 70 |
| Connect Biopharma Holdings | 64 |
| OnKure Therapeutics | 45 |
| Milestone Pharmaceuticals | 38 |
| Unicycive Therapeutics | 22 |
| Outlook Therapeutics | 17 |
KZIA News
- 22 hours ago - Kazia Therapeutics price target raised to $40 from $34 at BTIG - TheFly
- 1 day ago - Kazia Therapeutics announces new preclinical, translational data on paxalisib - TheFly
- 1 day ago - Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy - PRNewsWire
- 1 day ago - Kazia Therapeutics expands paxalisib trial into HR+/HER2- breast cancer - TheFly
- 1 day ago - Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer - PRNewsWire
- 1 day ago - Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering - PRNewsWire
- 5 days ago - Kazia Therapeutics 2.58M share Spot Secondary priced at $15.50 - TheFly
- 5 days ago - Kazia Therapeutics announces pricing of $120M public offering - TheFly